Aliqopa（copanlisib）

[Drug Description of Aliqopa(Copanlisib)]

The US Food and Drug Administration (FDA) recently approved Aliqopa(copanlisib) for the treatment of adult recurrent follicular lymphoma. These patients have received at least two treatments called systemic therapy.

Aliqopa is a kinase inhibitor that works by blocking several enzymes that promote cell growth. Aliqopa is a new type of intravenous PI3K inhibitor, and its inhibitory activity is mainly aimed at PI3K-α and PI3K-δ isomers expressed in malignant B cells.

Aliqopa has obtained accelerated approval, and FDA allows the use of clinical trial data to approve drugs for treating serious diseases to meet unmet medical needs, which are considered to predict the clinical benefits of patients. Further clinical trials are needed to confirm the clinical benefits of Aliqopa, and sponsors are conducting these studies.

[Aliqopa(Copanlisib) specification]

This product is an injection with the specification of 60mg/ vial.

[Usage and dosage of Aliqopa(Copanlisib)]

A vial of 60mg, administered intravenously for more than 1 hour, is used on the 1st, 8th and 15th days, and every 28 days is a course of treatment; Adjust the dose in case of toxic reaction.

[experimental data of Aliqopa(Copanlisib)]

Today’s approval is based on data from a single-arm trial involving 104 patients with follicular B-cell non-Hodgkin’s lymphoma who relapsed after at least two previous systemic treatments. This experiment measures how many patients have completely or partially contracted tumors (total response rate) after treatment. In this trial, the median complete or partial response of 59% patients was 12.2 months.